Results 321 to 330 of about 93,504 (350)

Role of mineralocorticoid receptor antagonists in kidney diseases

Drug development research (Print), 2020
Mineralocorticoid receptor (MR) antagonists, for example, spironolactone and eplerenone, are in clinical use to treat hypertension. Increasing evidence suggests that mineralocorticoid receptor activation causes the pathogenesis and progression of chronic
V. Patel, A. Joharapurkar, Mukul R Jain
semanticscholar   +1 more source

Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects

Nature Reviews Nephrology, 2021
J. Barrera-Chimal, I. Lima-Posada, G. Bakris, F. Jaisser   +3 more
semanticscholar   +1 more source

Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation.

Journal of Hypertension, 2019
BACKGROUND Adaptive immunity is crucial in cardiovascular and renal inflammation/fibrosis upon hyperactivation of mineralocorticoid receptor. We have previously demonstrated that dendritic cells can respond to mineralocorticoid receptor activation, and ...
P. Araos, C. Prado, Mauricio Lozano, S. Figueroa, Alexandra Espinoza, T. Berger, T. Mak, F. Jaisser, R. Pacheco, L. Michea, C. Amador   +10 more
semanticscholar   +1 more source

Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial (MIRAD trial)

Diabetes, obesity and metabolism, 2019
To investigate whether the mineralocorticoid receptor antagonist eplerenone has beneficial effects on liver fat and metabolism in patients with type 2 diabetes (T2D), the mineralocorticoid receptor antagonist in type 2 diabetes (MIRAD) trial.
M. Johansen, M. Schou, P. Rossignol, M. R. Holm, J. Rasmussen, Niels Brandt, M. Frandsen, E. Chabanova, F. Dela, J. Faber, C. Kistorp   +10 more
semanticscholar   +1 more source

Adverse Effects of Mineralocorticoid Receptor Antagonist Administration.

Current pharmaceutical design, 2019
BACKGROUND Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases.
M. Kallistratos, A. Pittaras, Iakovos Theodoulidis, Charris Grassos, L. Poulimenos, A. Manolis   +5 more
semanticscholar   +1 more source

Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone

Current Cardiology Reports, 2020
J. S. Rico-Mesa, A. White, Ashkan Ahmadian-Tehrani, A. Anderson   +3 more
semanticscholar   +1 more source

The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis

Kidney International Supplements, 2022
James M Luther
exaly  

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

Current Hypertension Reports, 2020
D. Sueta, E. Yamamoto, K. Tsujita
semanticscholar   +1 more source

New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure

JN. Journal of Nephrology (Milano. 1992), 2019
I. Capelli, L. Gasperoni, M. Ruggeri, G. Donati, O. Baraldi, G. Sorrenti, M. T. Caletti, V. Aiello, G. Cianciolo, G. La Manna   +9 more
semanticscholar   +1 more source

Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone

Proceedings of the National Academy of Sciences of the United States of America, 2005
Henk Karst, Günther Schütz
exaly